Actively Recruiting
Open Multicenter Study Evaluating Safety and Dosage of HRS-4508 in Adults With Advanced or Metastatic Solid Tumors
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2026-08-28
290
Participants Needed
1
Research Sites
26 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety, tolerability, and pharmacokinetics of HRS-4508 in adults with advanced or metastatic solid tumors. This phase 1 study aims to find a suitable dosage of HRS-4508 and assess its initial effectiveness in patients who have limited treatment options due to disease progression or lack of standard treatments. Participants will receive HRS-4508 monotherapy. The study monitors dose-limiting toxicity during the first 21-day treatment cycle and determines the maximum tolerated dose and recommended phase II dose after three weeks. Safety assessments occur every four weeks, and response to treatment is followed for up to approximately two years. Throughout the study, participants undergo regular evaluations including physical exams, laboratory tests, and imaging to measure tumor response per RECIST 1.1 criteria. Safety is closely monitored by tracking adverse events and their severity. The total study duration can extend up to two years, allowing for long-term observation of treatment effects and disease control.
CONDITIONS
Brief Title
A Clinical Study of the Safety, Tolerability, Pharmacokinetics, and Initial Efficacy of HRS-4508 Monotherapy in Patients With Advanced or Metastatic Solid Tumors
Research Team
X
Xiaoyu Zhu
Y
Yueling Wang
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here